Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Schnorr

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
Frontiers of Radiation Therapy and Oncology|February 15, 2002
High-dose rate brachytherapy--the Charité experienceDirk Böhmer, S Deger, S Dinges, et al.
Aktuelle Urologie|November 5, 2004
[The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer]D Daniltchenko, C Riedl, F Koenig, et al.
The Journal of Urology|April 29, 1998
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostateK Jung, A Meyer, M Lein, et al.
Clinical Chemistry|December 1, 1996
Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in bloodK Jung, L Nowak, M Lein, et al.
Clinical Chemistry|October 1, 1995
Rapid screening of PSA: evaluation of an immunochemical membrane strip testM Lein, K Jung, D Schnorr, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 13, 2001
Tumor M2 pyruvate kinase in plasma of patients with urological tumorsJ Roigas, G Schulze, S Raytarowski, et al.
International Journal of Cancer|January 8, 1998
Factors influencing the ratio of free to total prostate-specific antigen in serumA Meyer, K Jung, M Lein, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 15, 1996
What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?K Jung, L Nowak, M Lein, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 30, 2000
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancerC Stephan, K Jung, M Lein, et al.
Der Urologe. Ausg. A|January 4, 2001
[Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients]J Roigas, G Schulze, S Raytarowski, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
Frontiers of Radiation Therapy and Oncology|February 15, 2002
High-dose rate brachytherapy--the Charité experienceDirk Böhmer, S Deger, S Dinges, et al.
Aktuelle Urologie|November 5, 2004
[The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer]D Daniltchenko, C Riedl, F Koenig, et al.
The Journal of Urology|April 29, 1998
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostateK Jung, A Meyer, M Lein, et al.
Clinical Chemistry|December 1, 1996
Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in bloodK Jung, L Nowak, M Lein, et al.
Clinical Chemistry|October 1, 1995
Rapid screening of PSA: evaluation of an immunochemical membrane strip testM Lein, K Jung, D Schnorr, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 13, 2001
Tumor M2 pyruvate kinase in plasma of patients with urological tumorsJ Roigas, G Schulze, S Raytarowski, et al.
International Journal of Cancer|January 8, 1998
Factors influencing the ratio of free to total prostate-specific antigen in serumA Meyer, K Jung, M Lein, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 15, 1996
What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?K Jung, L Nowak, M Lein, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 30, 2000
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancerC Stephan, K Jung, M Lein, et al.
Der Urologe. Ausg. A|January 4, 2001
[Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients]J Roigas, G Schulze, S Raytarowski, et al.
Pageof 12